NasdaqGM - Nasdaq Real Time Price USD

Rocket Pharmaceuticals, Inc. (RCKT)

22.60 -1.03 (-4.36%)
As of 11:31 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Kinnari Patel M.B.A., Pharm.D. Head of R&D, President & COO 849.93k -- 1980
Mr. Mayo Pujols Chief Technical Officer 649.71k -- 1970
Mr. Raj Prabhakar M.B.A. Chief Business Officer 619.13k -- 1975
Mr. Aaron Ondrey Chief Financial Officer -- -- 1977
Mr. Martin Louis Wilson J.D. General Counsel, Chief Compliance Officer & Chief Corporate Officer 149.95k -- 1976
Kevin Giordano Director of Corporate Communications -- -- --
Ms. Isabel Carmona J.D. Chief People Officer -- -- --
Mr. Jonathan Schwartz M.D. Chief Medical & Gene Therapy Officer 557.79k 12.52M 1965
Dr. Gayatri R. Rao J.D., M.D. Senior VP of Clinical Safety & Chief Regulatory Officer -- -- --
Mr. Carlos Martin Chief Commercial Operations & Revenue Officer -- -- --

Rocket Pharmaceuticals, Inc.

9 Cedarbrook Drive
Cranbury, NJ 08512
United States
609 659 8001 https://www.rocketpharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
268

Description

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Corporate Governance

Rocket Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 6; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024 - May 06, 2024
Rocket Pharmaceuticals, Inc. Earnings Call

Related Tickers

RARE Ultragenyx Pharmaceutical Inc.
43.05
-2.78%
 
IMCR Immunocore Holdings plc
57.91
-0.96%
 
SWTX SpringWorks Therapeutics, Inc.
44.20
+1.88%
 
KRYS Krystal Biotech, Inc.
155.84
-2.02%
 
OLMA Olema Pharmaceuticals, Inc.
9.71
-4.33%
 
DYN Dyne Therapeutics, Inc.
23.84
-4.58%
 
RNA Avidity Biosciences, Inc.
23.73
-5.44%
 
BPMC Blueprint Medicines Corporation
89.14
-3.38%
 
RVMD Revolution Medicines, Inc.
34.95
-1.81%
 
APGE Apogee Therapeutics, Inc.
45.69
-1.83%